DAFNA Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-438,884
| Closed | -$2.65M | – | 90 |
|
|
2019
Q4 | $2.65M | Hold |
438,884
| – | – | 0.91% | 25 |
|
|
2019
Q3 | $1.58M | Sell |
438,884
-166,000
| -27% | -$640K | 0.59% | 42 |
|
|
2019
Q2 | $1.62M | Sell |
604,884
-16,298
| -3% | -$48.1K | 0.61% | 46 |
|
|
2019
Q1 | $1.84M | Sell |
621,182
-9,000
| -1% | -$22.1K | 0.79% | 38 |
|
|
2018
Q4 | $1M | Sell |
630,182
-217,454
| -26% | -$615K | 0.5% | 48 |
|
|
2018
Q3 | $3.12M | Sell |
847,636
-100,000
| -11% | -$298K | 1.28% | 26 |
|
|
2018
Q2 | $2.68M | Buy |
947,636
+79,364
| +9% | +$270K | 1.26% | 24 |
|
|
2018
Q1 | $3.22M | Sell |
868,272
-80,000
| -8% | -$262K | 1.57% | 23 |
|
|
2017
Q4 | $2.73M | Buy |
948,272
+230,000
| +32% | +$836K | 1.47% | 24 |
|
|
2017
Q3 | $3.23M | Buy |
718,272
+451,772
| +170% | +$2.01M | 2% | 13 |
|
|
2017
Q2 | $1.22M | Buy |
266,500
+70,000
| +36% | +$281K | 0.87% | 37 |
|
|
2017
Q1 | $827K | Hold |
196,500
| – | – | 0.7% | 41 |
|
|
2016
Q4 | $812K | Buy |
196,500
+10,000
| +5% | +$53.2K | 0.71% | 43 |
|
|
2016
Q3 | $1.51M | Sell |
186,500
-50,000
| -21% | -$425K | 1.05% | 35 |
|
|
2016
Q2 | $1.84M | Hold |
236,500
| – | – | 1.46% | 20 |
|
|
2016
Q1 | $1.83M | Hold |
236,500
| – | – | 1.58% | 20 |
|
|
2015
Q4 | $2.55M | Sell |
236,500
-243,800
| -51% | -$2.22M | 2.27% | 14 |
|
|
2015
Q3 | $3.32M | Hold |
480,300
| – | – | 3.29% | 5 |
|
|
2015
Q2 | $4.25M | Buy |
480,300
+238,700
| +99% | +$2.26M | 3.6% | 4 |
|
|
2015
Q1 | $2.38M | Buy |
241,600
+44,100
| +22% | +$551K | 1.83% | 14 |
|
|
2014
Q4 | $2.42M | Buy |
197,500
+171,500
| +660% | +$2.09M | 1.91% | 16 |
|
|
2014
Q3 | $259K | Buy |
+26,000
| New | +$241K | 0.26% | 48 |
|
|
2013
Q4 | – | Sell |
-121,800
| Closed | -$368K | – | 53 |
|
|
2013
Q3 | $368K | Hold |
121,800
| – | – | 0.4% | 43 |
|
|
2013
Q2 | $996K | Buy |
+121,800
| New | +$930K | 1.46% | 16 |
|
DAFNA Capital Management's ACHN Position: Q1 2020 in Review
DAFNA Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 438,884 shares — an estimated $2.65M sold.
DAFNA Capital Management first reported a position in ACHN in Q2 2013 and held it in 24 quarters. The position peaked at $4.25M in Q2 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- DAFNA Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- DAFNA Capital Management sold 438,884 Achillion Pharmaceuticals shares in Q1 2020, an estimated $2.65M.
- DAFNA Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 24 quarters.
- DAFNA Capital Management's Achillion Pharmaceuticals position peaked at $4.25M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on DAFNA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.